Top

Category: Mergers and Acquisitions


Mergers and Acquisitions, News

Merck signs $1.2bn supply deal with US government for Molnupiravir

June 9, 2021

Via: PMLiVE

The treatment, being developed by Merck in collaboration with Ridgeback Biotherapeutics, is currently being evaluated in a phase 3 clinical trial. The trial, know as the MOVe-OUT study, is evaluating molnupiravir in the treatment of non-hospitalised patients with laboratory-confirmed COVID-19 […]


Mergers and Acquisitions, News

Biotech venture capital still booming as venBio raises another $550M

June 3, 2021

Via: Biopharma Dive

Venture capitalists interested in biotech have been able to raise money with unprecedented ease over the past several years. Polaris Partners, 5AM Ventures, Third Rock Ventures, Versant and venBio are just some of the firms to have secured hundreds of […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Novo Nordisk partners with Heartseed on heart failure cell therapy

June 1, 2021

Via: PMLiVE

HS-001, Heartseed’s lead asset, is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC). The therapy is currently being developed as a treatment for heart failure. Heartseed is already planning to launch a phase 1/2 […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

CSL closes deal for UniQure gene therapy in hopeful sign for M&A

May 6, 2021

Via: Biopharma Dive

According to Paul Matteis, an analyst at Stifel, the closing of the deal removes a question mark hanging over UniQure’s stock. Regulators, especially those in the U.S., are taking harder looks at pharmaceutical acquisitions, suggesting that approval of the UniQure-CSL […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Two biotechs team up to bring CRISPR to ‘natural killer’ cell therapy

May 6, 2021

Via: Biopharma Dive

Two biotechs aim to broaden the reach of cancer immunotherapy by applying gene editing tools to an emerging form of cell therapy through a wide-ranging collaboration. The agreement, between CRISPR Therapeutics and Nkarta, includes three components. The biotechs will first […]


Mergers and Acquisitions, News

Pfizer Acquires Amplyx Pharmaceuticals

April 29, 2021

Via: Contract Pharma

Pfizer has acquired Amplyx Pharmaceuticals, a privately-held company dedicated to the development of therapies for immune system disorders. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. Financial terms were […]


Manufacturing, Mergers and Acquisitions, News, Research and Development

Samsung and TG Therapeutics to Expand mAb Manufacturing Collaboration

April 27, 2021

Via: Biopharm International

Samsung Biologics announced on April 26, 2021 that it has expanded its 2018 contract manufacturing deal with TG Therapeutics, a US based healthcare company, for the supply of TG’s ublituximab, an investigational anti-CD20 monoclonal antibody (mAb). Since the start of […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Collaboration is key to advancing cell therapy research

April 22, 2021

Via: Pharmaphorum

Cell therapy is a treatment involving the genetic modification and reprogramming of a patient’s immune cells to target their own specific cancer, making it a truly individualised medicine. It’s one of the most promising – and one of the most […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

April 21, 2021

Via: PMLiVE

Following the amended agreement, Vertex will now lead the global development, manufacturing and commercialisation of the gene therapy CTX001, with support from CRISPR Therapeutics. In December, Vertex and CRISPR Therapeutics announced new, early-stage data from a total of ten patients […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

SparingVision to buy GAMUT and potential Luxturna eye gene therapy competitor

April 20, 2021

Via: Pharmaphorum

GAMUT’s lead product, now SPVN20, is a novel, mutation-agnostic gene therapy, which aims at restoring the function of dormant cone cells in the retina. If approved it would compete with Novartis’ Luxturna (voretigene neparvovec), the gene therapy from Roche/Spark Therapeutics, […]


Mergers and Acquisitions, News

Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million

March 23, 2021

Via: BioSpace

Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa” or the “Company”), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration

February 9, 2021

Via: BioSpace

Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the expansion of its T cell engineered therapy […]